Title

Presentation

Glaukos Corporation misses on earnings expectations. Reported EPS is $-0.63 EPS, expectations were $-0.56. Glaukos Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Welcome to the Glaukos Corporation’s Fourth Quarter and Full Year 2023 Financial Results Conference Call. Copies of the company’s press release and quarterly summary document, both issued after the market closed today, are available at www.glaukos.com. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] This call is being recorded, and an archived replay will be available online in the Investor Relations section at www.glaukos.com. I will now turn the call over to Chris Lewis, Vice President of Investor Relations and Corporate Affairs. Please go ahead.

Chris Lewis: Thank you and good afternoon. Joining me today are Glaukos’ Chairman and CEO, Tom Burns; President and COO, Joe Gilliam; and CFO, Alex Thurman. Similar to prior quarters, the company has posted a document on its investor relations website under the financials and filings quarterly results section titled quarterly summary. This document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies, any forward statements or guidance we may make. This document is designed to be read by investors before the regularly scheduled quarterly conference call.

As such, for this call, we will make brief prepared remarks and transition into a question-and-answer session. To ensure ample time and opportunity to address everyone’s questions, we request that you limit yourself to one question and one follow-up. If you still have additional questions, you may get back into the queue. Please note that all statements other than statements of historical facts made on this call that address activities, events or developments we expect, believe, or anticipate will or may occur in the future are forward-looking statements. These include statements about our plans, objectives, strategies and prospects regarding, among other things, our sales, products, pipeline technologies and clinical trials, U.S. and international commercialization, market development efforts, the efficacy of our current and future products, competitive market position, regulatory strategies and reimbursement for our products, financial condition and results of operations as well as the expected impact of general macroeconomic conditions including foreign currency fluctuations on our business and operations.

These statements are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Therefore, they may cause our actual results to differ materially from those expressed or implied by forward-looking statements. Review today’s press release and our recent SEC filings for more information about these risk factors. You’ll find these documents in the Investors section of our website at www.glaukos.com. Finally, please note that during today’s call, we will also discuss certain non-GAAP financial measures, including results on an adjusted basis. We believe these financial measures can facilitate a more complete analysis and greater transparency into Glaukos’ ongoing results of operations, particularly when comparing underlying results from period-to-period.

Please refer to the tables in our earnings press release available in the Investor Relations section of our website for a reconciliation of these measures to the most directly comparable GAAP financial measure. With that, I will turn the call over to Glaukos’ Chairman and CEO, Tom Burns.

See also 12 SUVs With the Highest Resale Value in 2024 and 11 Best Semiconductor Stocks To Invest In for the AI Boom.

Thomas W. Burns: Okay. Thank you, Chris. Good afternoon, and thank you all for joining us today. Glaukos reported today record fourth quarter consolidated net sales of $82.4 million up 16% on a reported basis and 15% on a constant currency basis versus the year ago quarter. For the full-year 2023, consolidated net sales of nearly $315 million grew 11% on a reported basis and 12% on a constant currency basis versus 2022. We are also reaffirming our full-year 2024 net sales guidance range of $350 million to $360 million. These record results, which further exceeded our preliminary pre-announcement from early January were driven by broad-based double-digit growth across our Glaucoma and Corneal Health franchises globally. Our strong fourth quarter performance caps-off a successful year of execution, both from a commercial and development perspective, leaving us ideally positioned as we enter into what should be a transformative period for our company in the years to come.

From a commercial perspective, strong execution of key strategies within each of our core franchises drove this out performance. Within our U.S. Glaucoma franchise we drove over sales of $38.7 million and growth of 10% year-over-year, driven primarily by the continued commercial rollout of iStent infinite. Market receptivity and adoption of iStent infinite remains strong with surgeon feedback most commonly highlighting the benefits of its three stent solution favorable safety profile and streamlined injector system. Alongside our commercial efforts, we also continue to advance key market access initiatives for iStent infinite with all MAC covering on a case-by-case basis, including two with LCAs in place. We will continue to monitor the various MAC processes and policies as we remain supportive of expanding broad access to interventional glaucoma tools for physicians and for patients.

Moving on, our international glaucoma franchise delivered sales of $21.9 million on strong year-over-year growth of 25% on a reported basis and 23% on a constant currency basis. The strong growth was once again broad-based as we continue to scale our international infrastructure and execute our plans to drive MIGS forward as a standard of care in each region and every major market in the world. And finally, our Corneal Health franchise delivered record sales of $21.8 million, a 19% year-over-year growth, including Photrexa record sales of $19.2 million on a year-over-year growth of 26%, as our key initiatives continue to take hold in support of this important business. Shifting gears to the development front, as you know, during the fourth quarter, we were delighted to announce FDA approval of iDose TR, our revolutionary micro-invasive, injectable therapy designed to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

iDose TR is a first of its kind intracameral procedural pharmaceutical designed to deliver glaucoma drug therapy for up to three years. Following approval, our teams have been hard at work executing the initial phases of our detailed coordinated launch plan. In conjunction with these efforts, we’re pleased to announce that just last week, multiple surgeons successfully completed their first commercial cases of iDose TR. We’re happy to report all of these cases went extremely well and early feedback from the small group of surgeons has been very positive. Looking ahead, we plan to continue advancing a methodical controlled launch over the first half of 2024 with a primary focus on surgeon training and establishing market access. As we refine and optimize our training and skill transfer to our sales force and surgical community, we will continue to expand our training and broader launch efforts over the course of 2024.

We are in a powerful position to leverage our established best-in-class glaucoma sales force and commercial organization to drive the iDose launch. Speaking of which, earlier this month, we held our global sales meetings where most of the focus here in the U.S. was on iStent infinite and iDose TR. It was evident throughout the productive meeting that our glaucoma sales force is excited and prepared to execute our plan. Alongside that, we are progressing several market access reimbursement initiatives designed to drive fulsome coverage and payment for the iDose TR procedural pharmaceutical over time. On that front, first, we successfully submitted our permanent J-code application in late December, which should allow for it to become effective in the second half of 2024 based on the CMS cycle for J-codes.

Until then, we are launching iDose TR with a temporary miscellaneous C-code anticipate measured adoption over this initial period until the permanent J-code is in place and we’ve expanded our surgeon training initiatives. Next, we are working to establish payment for the new Category III code 0660T that will cover the procedural component of iDose TR. This includes the establishment of the facility fee through an APC classification from CMS, which we expect to become effective April 1. We will also be working with MAC to secure professional fee coverage and payment over the course of 2024. Finally, our iDose TR commercial launch will be supported by robust set of peer-reviewed literature. During the fourth quarter, the first iDose TR publication was published in the Journal of Drugs and summarizes the Phase 2b three year outcomes.

More recently, another TR manuscript published in ophthalmology and therapy highlighted favorable Phase 3 12-month results. Looking ahead, there are an additional ten articles planned to be published in leading journals, including a manuscript that was just accepted by ophthalmology, which highlights iDose’s TR’s Phase 3 three month results. So to summarize, the response we received from surgeons in the broader ophthalmic community since we announced FDA approval for iDose TR has been overwhelmingly positive and reaffirms our view that with the launch of iDose TR, we are pioneering a brand new category of procedural pharmaceuticals that has the potential to reshape glaucoma management as we know it today. We’re excited to now be in the initial phases of bringing this transformative technology to market and in doing so expanding the treatment alternatives for patients suffering with glaucoma and ocular hypertension.

Beyond iDose, we continue to prudently invest in and successfully advance our robust pipeline of novel promising platform technologies that we believe have the abilities to significantly expand our addressable markets and fundamentally transform our company over time. This includes Epioxa, our next generation corneal cross-linking therapy for which we continue to progress towards trial completion in the second Phase 3 pivotal study and remain on-track for data readout in the second half of this year, supporting our targeted NDA submission by the end of 2024. In terms of our earlier stage pipeline, we commenced three new clinical trials during the fourth quarter of 2023, including one, a PMA clinical trial for iStent infinite in mild-to-moderate glaucoma patients.

Two, a Phase 2a study for iLution Travoprost. And three, a first-in-human clinical development program for GLK-401, our intravitreal multi-kinase inhibitor retinal program in wet AMD patients. In 2024, we’ll continue to drive our robust pipeline forward with additional plans, which include commencing a U.S. IDE trial for the PreserFlo MicroShunt, commencing a Phase 3 study for iDose TREX, our next-generation iDose therapy, and finally completing enrollment in our Phase 2 trials for our iLink third-generation therapy. So, as you can see, we have a lot to be excited about when it comes to the significant potential value that we believe our pipeline programs may create. At the same time, as we’ve discussed, we continue to prioritize the cadence of our investments as we strive to strike the right balance of risk-based spending and our capital position now and in the future.

In conclusion, I think it’s fitting to remind you of our company mantra, “We’ll Go First”, which for us is more than just a company tagline. Rather, it’s something that defines who we are as an organization and how we lead every day. We are ready to deliver in 2024 and beyond as we execute our commercial launch plans for iDose TR along with iStent infinite. Our foundation is strong and we’re ideally positioned to continue transforming vision for the benefit of patients worldwide. So with that, I’ll open the call to questions. Operator?

Operator: Thank you. [Operator Instructions] We’ll go first to Tom Stephan at Stifel.

Tom Stephan: Great. Hey, guys. Thanks for the questions. Maybe I’ll start with guidance. Joe or Alex, any framework you can provide on how much of iDose is factored into 2024 guidance? And then also what are some of the key inputs supporting that outlook?

Joseph E. Gilliam: Sure. Hey, Tom, it’s Joe. I’ll start off and Alex will add some color he can. Maybe first I’ll start from a macro perspective on the guidance itself. I mean, obviously, we were pleased to see the business continue to deliver and the momentum as we exited 2023, we’re entering 2024. And, I think that the guidance we established overall really implies another year of accelerating growth as we focus on putting in place really the foundational building blocks that we believe will enable the next really decade of growth for our company. I said this, I think, on one of the calls either around the Investor Conference earlier this year or in December when we first gave guidance. There are a variety of scenarios and drivers for our business in 2024 and even within the U.S. Glaucoma franchise of which iDose is really one of those.

And so, I certainly acknowledge and respect the importance of trying to dive a little bit deeper on the specificity around the numbers associated with iDose. I think it’s a little early to get too granular there. Clearly, it’s going to be an increasingly material driver as we make our way through the year and certainly as we enter 2025. And at some point here in the coming quarters, we’ll provide additional disclosure on the actual revenues of iDose as we really transition from, as Tom said, the early access phase into a full launch.

Tom Stephan: Got it. Makes sense. That’s fair. And then just on the iDose label, I know it’s only been a couple of months since approval, but Tom, any updates on the label as it relates to single administration? Have you been able to gather, I guess, any additional color from FDA on their decision? And then maybe more importantly, what the path forward for Glaukos is from here in that regards? Thanks for taking the questions.

Thomas W. Burns: Yes, Tom. I’d be happy to answer it. And so, let me first say that we’re poised for success today given the current label. Even with the current limitation in all our channel checks with our clinicians and surgeons, we see no impediment to the appetite for the use of the iDose product. And so, that’s very encouraging. But to answer your question directly, we’re in the process of repetition to the FDA for re-administration of the iDose device. And, as you’re probably aware within CDER right now, the drug division, there’s a change in the guard. And so, we’re waiting for that transition to happen and the dust to settle, and then we’ll put our petition before that court. And we’re hopeful for a successful conclusion.

In the event that we’re not, remember that we already have iDose TREX, which again contains approximately twice the amount of medication of the iDose that’s planned to enter clinical trial by the end of the year. And so, by our best thinking, we’re targeting a commercial approval for that product in 2028. So, if you think about it, that iDose TREX could become the next re-implantation product for our current iDose products and initiatives. So, I feel like we’re covered in all respects. I feel good about our path forward. We’re hopeful to be successful on repetition in the FDA. We have a sophisticated argument to make to them, but having said that, we’re covered in either of that.

Tom Stephan: Very helpful. Thanks, Tom.

Thomas W. Burns: You’re welcome. Thanks, Tom.

Operator: We’ll go next to Ryan Zimmerman at BTIG.

Ryan Zimmerman: All right. I’m going to try and ask a similar question on iDose in a different way and press my luck here a little bit. But, when you talk about the controlled launch guys, what does that mean? How many surgeons are you trying to get comfortable with an iDose? At what point do you transition to a broader launch regardless of maybe the reimbursement milestones that are up ahead? Just to help us kind of frame how much experience you’re looking for with iDose initially?

Joseph E. Gilliam: Hey, Ryan. It’s Joe. We’ll try not to have you hit a whammy here, but I will give you a little bit of color around kind of where we’re at, where we’re going. Hopefully, it’s consistent with what we talked about during the original approval call. Right now, we’re officially in the early access phase of the launch. And the great news, as Tom mentioned in the prepared remarks, we now have the first procedures having been completed last week as a part of that. That’s a big step organizationally or through our national sales meeting. We’ve begun that early access phase with a handful of docs. And, I think it’s important to note that it is limited in the scope. The goal of that early access phase is really designed to help us refine our training algorithms and establish confidence within our sales force and iron out, any early market access challenges that inevitably come with a product launch like this.

We will transition in the coming months to a broader launch. But like we’ve said in the past, that really goes from, crawling to walking to jogging to running. The objective there is that as we move into those early launch phase that we’ve got all of our reps out, starting with their starter cases, training, one, maybe two doctors at the beginning. And then as they continue to refine their algorithms and their experience, we’ll open that up more broadly as we get into the second half. It clearly, as we’ve said before, starts to hit a stride as you get into the fourth quarter and that’s by design because that also happens to match up with where you expect the market access side of the equation to start to provide a little bit more clean path forward too as you’ve got a fully established J-code, a published ASP and all the things that come alongside that.

So, it really will be a somewhat, I’ll call it linear release, if you will, of our efforts between now and that fourth quarter time frame where we hope to start really running as we then sprint into 2025.

Ryan Zimmerman: Okay. Second question for me, turning to infinite, you guys are going to pursue a label expansion in mild-to-moderate patients. How much of that a gating factor do you think to adoption in current usage of infinite? When you think about how it’s being used today, where it can go and maybe kind of talk about it in the context of both combo cataract and also standalone, as you pursue that label?

Thomas W. Burns: Yes, Ryan. I’m happy to address that. So first of all, let’s talk about the study itself. So, we’re going to do a multi-center prospective study, which will be looking at mean our IOP reduction of greater than 20% from baseline in 12-months with a pre-specified endpoint that we negotiate with the FDA. And so we feel like we’re in a confident position targeting approval at the tail end of this clinical trial given the demonstrable performance we’ve had with the product up-to-date. I think when we look at the marketplace in the LATAM serially, we know that the current marketplace for patients who failed on surgical and medical therapy we’re estimating at about 200,000 patients, right. And so, when we expand and we look at going to mild-to-moderate patients, we believe by our estimations that we’ll be looking at additional 400,000 to 500,000 patients that we would be covering by doing so.

So that, in and of itself gives an expression of how we intend to expand the market. I think the product will be used equally. I think as we get these get the approvals, I think there’ll be a strong initiative as we move forward with interventional glaucoma where people will start to feel strong confidence in using this in standalone cases. And certainly, our upgrade to 5493 on the APC side doesn’t hurt us as a financial incentive for surgeons to be doing the right therapy for their patients. I think as well on the combo cataract side, it makes sense, whereas particularly when we have a broad label that surgeons will feel very comfortable down to the very early innings of glaucoma and using this product in combination with cataract surgery.

Why wouldn’t you? You have three stents versus two stents in this case, and we showed demonstrable additive effect with those different products. So, I feel like that’s the way this will come on. And one of the things that I feel very strongly about is that over time, surgeons will begin to use iStent infinite in conjunction with iDose. And so, why do I say that? Because iStent infinite is showing a strong ability to re-establish physiologic outflow through the trabecular meshwork. iDose works on a different part of the eye, the uveoscleral system. And so, using these products in combination should provide a very robust combinatorial care and procedure therapy for surgeons as they move forward. And we think that within the Medicare fee for service system, there’s going to be no impediments.

There’s two separate CPT codes, different mechanisms of action and these are different product classes. And when you think about it, 50% of patients right now that use topical meds are on two or more medications. So, combination therapy rules half of the current identified diagnosed glaucoma patients. And so, we think that this will be an extraordinary opportunity in combination therapy. As we get into commercial payers and Medicare advantage, there’ll be some restrictions just like there is with standalone treatments with infinite and with iDose. But we’re highly encouraged. I love the double whammy of having both these harbingers and catalysts giving us the fulcrum to create the interventional glaucoma market space.

Ryan Zimmerman: Thanks, Tom. Thank you for taking the question.

Thomas W. Burns: Okay. Thanks, Ryan.

Operator: We’ll take our next question from Larry Biegelsen at Wells Fargo.

Larry Biegelsen: Hey, guys. Thanks for taking the question. Tom, starting up on the iDose, obviously the ASP got a lot of attention when you announced it. Love to hear from you the reaction from any payers or physicians and your confidence that you’ve priced this right? And just secondly, your confidence that the surgeon fee is going to be adequate? And I have one follow-up.

Thomas W. Burns: Yes. I’d be happy to address that, Larry. So as you know, we did our homework over the last couple of years. We’ve done multiple pharmacoeconomic, different approaches to the treatment of glaucoma using the iDose therapy. We’ve done Markov transition probability analysis. We met with payer groups. We licensed and looked at an external group to be able to go out to payers and pre-talk about the pricing of this product, although we didn’t disclose what product it was, but we talked about the nature of the attributes. And we are getting positive signals across the board. And so, the short answer to your question is, once we look at and show surgeons where this procedural pharmaceutical lines up, given the other procedural pharmaceuticals that have been available and codified within ophthalmology, this squares off very well somewhere in the median of those products.

As you know, Retisert, which is a three year steroid implant used for the treatment of uveitis, cost on the order of $18,000 to $19,000 We know that [Derista] (ph) is roughly $2,000 for a three to four month therapy. And when you impede it you start to look at that over a three year period, you start to get quite comfortable that we were, I hope, pressured in how we price the product. So having said all that, the response of surgeons, I think has been fulsome, has been understanding. I don’t see that as an impediment at all as we move forward. I think we’re going to have open field running with Medicare fee for service. I think as we get into commercial and medicare advantage patients, certainly they will do the same thing they did with [Derista] (ph), have some edits before you’re using this product.

But I don’t anticipate any impediments to utilization versus where we price the product. I think we hit it right where we should have.

Larry Biegelsen: And the surge in fee being adequate, I’ll just ask my follow-up. What happens next with the MIGS LCD or what’s the assumption in the guidance? What are you assuming for infinite? Case by case is not probably what ideal for you? And is there any turbulence in the market still from the noise from this LCD? Thanks.

Thomas W. Burns: Let me address I didn’t address your second question on prophyse. Let me do so before I turn it over to Joe. If we look at what’s happening with iStent infinite, which is a very like procedure and we’d see at WPS and First Coast at least, the first numbers are coming in at certainly greater than $600, and we know that cataract surgery right now average national payment is about $5.25. I think we’re going to sell somewhere in that range. Some of the ranges have been as high as $1,000 in the early innings for iStent infinite. So as different MACs start to look at this procedure, I think they’re going to start to cross walk this over pretty similarly to what we see with iStent infinite. So I wanted to answer your question before I turn it over to Joe.

Joseph E. Gilliam: Hi Larry, on the LCD front, I think this is one of those scenarios obviously that we assess as we set the overall guidance and there’s a range of outcomes there perhaps certainly less material than iDose as you think about the drivers for 2024. But in general, I think it’s at this point largely status quo, at least for now with perhaps an overlay of being cautious at the account level until more definitive clarity is established. The next steps and the timing for MAC policy changes remains unclear at this point, but we do expect to hear from them again. And, and in that regard, our priorities really remain unchanged. We’re focused on protecting the rights of our customers to make clinical decisions on behalf of their site threatened patients. But at this stage, we’re in the waiting game to determine where the MAC go next.

Larry Biegelsen: Thanks a lot.

Operator: We’ll go next to Matthew O’Brien at Piper Sandler.

Matthew O’Brien: Good afternoon. Thanks for taking the questions. The Street’s modeling for iDose about $27 million, $28 million this year. Is that number a good number? Too high, too low in your opinion? And then those first cases, were they bilateral or single eye cases? And then I do have a follow-up.

Joseph E. Gilliam: Sorry. Matt, can you repeat that second part of the question? Oh, single eye. Yeah. For the rest of the Single eye. Yep. Yeah. So I’ll start with that. They were they were all signal I cases to at the start here, which is what you’d expect as a part of, the iDose launch. As it relates to the iDose number, I’ll stop short of commenting specifically on where the Street’s guidance is at. Maybe what I will do is provide a little bit more color and context around the franchises and their drivers of our overall guidance. And clearly, the US glaucoma franchise moves, front and center to why you guys are focused on that and asking questions around iDose. Our focus there is going to continue to be driving forward first the interventional glaucoma mindset.

And within that, trying to establish iStent infinite and then driving the training and market access and and early adoption with with iDose. Internationally, the business continues to scale, as you saw in the fourth quarter. With that, it comes to market access headwinds as government payers really seek to limit expenditures as you scale. Most recently, we’ve seen that emerge in Switzerland, for example. We’ll see it elsewhere. We’ve seen it in the past, and we’ll continue to experience that. In parallel, we expect to see continued efforts by competition in those markets and probably even a little bit of currency headwind as we sit here today going into the year. And on the cornea side, while we were very pleased with the growing momentum we saw in the fourth quarter, we’ll probably face some new headwinds in 2024.

As some of you may be aware, the $0 floor for Medicaid rebates expired on December 31st. And with that, we’re going to see some incremental government rebating on a year-over-year basis. And we’ll probably also see some continued device related selling headwinds as the efficacy gets increasingly in focus for both our customers and our sales force. If you think about that math directionally, kind of where does that put us in the guidance range we gave? I think that we’re comfortable that interventional glaucoma franchise should deliver kind of lowish double digit year-over-year growth for the year, that corneal health should deliver mid-single digit year-over-year growth for the year, taking into consideration what I just mentioned. And then ultimately, that implies the US glaucoma, some high teens type growth, which is, of course, going to be weighted towards the back half of the year.

So I think as you put all that together and maybe most importantly, it points out accelerating trends within our overall franchises and what we think, is a pretty strong exit loss, if you will, when you think about coming out of 2024 and into 2025, particularly within that US glaucoma business.

Matthew O’Brien: Okay. Appreciate that, Joe. And then that kind of ducktails into the next question. You started covering all this, but in what you’re just saying, but I mean that’s a dramatic slowdown in the US glaucoma business excluding whatever revenues would come up before iDose and then kind of same thing OUS. And I know you’re talking about Sweden, but I don’t think it’s that big of a market, maybe I’m wrong. So why would they slowdown that dramatically in many of these areas, especially Cornell Health, which has had a monster Q4?

Joseph E. Gilliam: Yeah. So I mean, I think I just sort of covered that. Let me clarify a couple of things that you just you just said there. I think in the in the context, I won’t repeat my comments around some of the drivers there obviously, in each of those businesses. I’ll focus on what you said around the international, the US glaucoma side of things. On the international side, look, if you continue to scale it with Switzerland, it is not, the largest or even our European markets, but it does matter when you’re thinking about that that growth dynamic. When you bridge from the currency headwinds that we expect a couple of percent probably 2% -ish at this point and you think about some of the competitive dynamics that continue to evolve out there.

Combine that with what is a relatively difficult first half comp, if you go back and look at our international business, it was pretty clear that we were running at elevated levels in the first half of last year. But despite the continued growth tailed off a little bit from an absolute basis in the second half probably as procedures started to normalize a bit, on a global basis in the second half. So you have to factor each of those things in. As it relates to the US glaucoma, I don’t think I follow that there. In fact, if you imply from what I just said in terms of, high teens growth for the year, and that accelerating over the course of the year into the back half, that that overall in any way you cut it is actually an accelerating performance, which is what you’d expect with both the impact from iStent infant as well as obviously iDose, coming into 2024.

Matthew O’Brien: Okay. We can follow-up offline. Thanks.

Joseph E. Gilliam: Thanks, Matt.

Operator: We’ll go next to Margaret Kaczor at William Blair.

Margaret Kaczor: Hey. Good afternoon, guys. Thanks for taking the questions. I wanted to maybe start I’m not going to speak again. Sorry. I’m going to be, you know, number five today on this. But, I wanted to see if there’s any additional background on the initial surgeon patient cohorts for these first few iDose cases. These patients that have been waiting for a long time in the queue? Are these clinicians doing multiple iDose procedures in a day? Is there already in the ASC? Anything like that would be useful. Thank you.

Joseph E. Gilliam: Hi, Margaret. It’s Joe. I mean, obviously, it’s a little early with these cases having just started, last week to draw any discernible trends. I think that for majority of these patients, I would say they’re clearly, standalone patients, that these early surgeons have deemed to be straightforward in the context of bringing them into the iDose procedure. Whether or not they were previously treated with different solutions and maybe even in iDose trial, etcetera. Historically, there’ll be a mix of that as we get going here. But I think the most important thing there is that the surgeons out of the gate are really focused on providing a standalone therapy and care for these patients.

Margaret Kaczor: Okay. Fair enough. And then I wanted to maybe move over to Epioxa, NDA submission, by the end of the year. What’s the vision for the products, kind of your expectations on timing and level setting us maybe on the opportunity from a prevalence perspective, placebo cost perspective, etcetera? Thanks.

Thomas W. Burns: Yes, Margaret, I’m happy to take that one. And so as we said before, we’ll have the results for the second Phase 3 clinical trial by midyear or so we’ll be preparing an NDA. We’ll hope to be able to publish those results just before we file our NDA with the FDA. We’ll look for a 10 month PDUFA day or thereabouts and will be approvable in the late part of 2025. And when you think about it, Epioxa, as we talked about before, is a highly different procedure. The fact that I don’t have to remove the corneal epithelium, to be able to perform the procedure is pretty extraordinary. The corneal epithelium, when it’s removed, does impede somewhat visual rehabilitation. It certainly is painful for the patient. And because of the extra time for visual rehabilitation, a lot of times it’s incongruent with the young patients that are having this procedure, which sometimes have to defer the procedures until spring break or summer until they have a little bit more time to spend at home and heal.

So we have the opportunity with Epioxa of having a new formulation, which has a surfactant in it, which aids in penetration. It has an oxygen perfusion goggles associated with it. So it bathes the eyes with oxygen, which is a really significant part of the procedure in order to get efficacy if you’re not removing the corneal epithelium and it’s done at a higher irradiation rate. So our hope and our challenge and opportunity is to be able to have this product meet the endpoint with the second Phase 3 trial. As you know, the first Phase 3 trial did meet the endpoint primary endpoint from the FDA. So we’re very hopeful that we’re able to do this with the second trial. And more importantly, we’re hopeful for getting this out to patients because of those factors that I talked about, more patients who can want to have this procedure.

It’s going to be far more timely with their schedules. It’s going to be far better in visual rehabilitation as we move forward. So for all these reasons, what I expect and what I will want to ensure is that we see a spike in usage and adoption with Epioxa moving forward. And so for all those reasons, we’re excited and moving forward. And again, Epioxa is just the first stage. We already have a third generation product that’s undergoing Phase 2 clinical trials. That’s a laser that will actually use a laser of irradiated light, which will more prescriptively and precisely be able to define an algorithm on the surface of the eye to be able to treat keratoconus. And so if you think about it, it looks like in MIGS where we continue to innovate and protect share and move forward and build the marketplace, we already have these chess pieces in place in Keratoconus as well, and we expect those to pay off both now and in the future.

Margaret Kaczor: Okay. Appreciate it guys.

Thomas W. Burns: Thanks, Margaret.

Operator: We’ll move next to Allen Gong at JPMorgan.

Allen Gong: Hi, team. Thanks for the question. I just had one quick one to start off just on, I guess, seasonality heading into next year. You ended the year with a stronger than expected quarter. Some of the headwinds that you’d feared might have been a little better than expected. And, you know, I understand that you don’t want to provide iDose, but just thinking about the underlying business ex-iDose, should we think of it as basically being a fairly normal year from a seasonality perspective?

Joseph E. Gilliam: Thanks, Allen. It’s hard to parse those between the two, but I’ll do my best. I think as you know, in normalized conditions, you typically see 22%, 23% of our revenues in the first quarter, 25% in the second, 24% to 25% in the third and call it 26% to 28% in the fourth. And not surprisingly, we do expect those patterns to be pretty disrupted this year, by the combination of both the growing infinite business as we continue to turn on the market access side of that equation as well as most materially the iDose launch over the course of 2024. I think the net effect of that should be a fairly material shifting of the seasonality, if you will, to the second half and in particular the fourth quarter. So it’s not entirely that disrupt is not entirely driven by iDose, but that is by far the biggest driver of a shift away from our traditional seasonality patterns.

Allen Gong: Got it. And then when I think about the margins for you this year, how should we think about what kind of leverage you can get from iDose? It’s the first year of launch, so I imagine it might be a little limited. But my sense is that this could ultimately be quite a profitable device for you. So now that we think about the fact that you’ve ramped up infinite and you’re going to be ramping iDose, where can, you know, gross margin, SG&A, R&D go this year?

Thomas W. Burns: Yeah. So, Allen, thanks for the question. So you’re right. We do expect iDose to be accretive in to our gross margin over time. And to your second point, for now we caution you with some conservatism as there could be some modest volatility in the margin as we ramp up iDose and go through a new product launch and the associated scaling that happens from a manufacturing standpoint. But that said, we expect the overall probably 2024 gross margin to land in that upper end of what we’ve always said was an 83% to 84% range. So we’re thinking probably plus or minus 84% for the year.

Operator: We’ll move next to Joanne Wuensch at Citi.

Joanne Wuensch: Thank you very much for taking the question. Two. One has to do also with the expense side of the income statement. Since you’re investing so much in not just research and development, but also in launching multiple new products. How do we think about operating expenses for 2024? And I’ll toss my second question on at the same time. One of the things I’m trying to figure out is how physicians are going to be spending their time. Do you think of the iDose launch as maybe cannibalizing more traditional MIGS procedures, complementary? Or how do we think about, how the physician spends his or her time having, now multiple types of products to use? Thanks.

Alex R. Thurman: You bet. Hey, Joanne. This is Alex. I’ll start with your OpEx question. So I think the way to think about 2024 is to expect that both to your point, both SG&A and R&D will grow in this year as we continue to invest in our iDose launch and the pipeline. The way I would counsel you to think about it is to start with our baseline 2023 adjusted operating expenses, which excludes the IP R&D and that number was about $360 million. And then I would assume about a 10% growth up to that base. So that would apply 2024 OpEx just shy of about $400 million for the year.

Joseph E. Gilliam: And then as it relates to iDose and the sort of overall procedure dynamics within the Glaukos framework, I think the right way to answer that is to look at it both over the short and the longer term. Certainly over the short term as we’re driving training and initial launch, I don’t expect it to have a significant impact, to obviously the dynamics within the practice and how they handle their time between, traditional MIGS products and the new class of procedural pharmaceuticals. Certainly, as we move forward, you can expect that with success, I think iDose likely will cannibalize to a certain extent some of those, traditional mixed procedures that surgeons get more and more confident in utilizing the product and the reimbursement associated with the etcetera and utilize it, whether it’s a standalone product or in combination with cataract surgery or in combination with other procedures, as Tom mentioned earlier, depending upon the needs of the individual patient.

But over the long term, our expectation is that iDose really becomes the cornerstone of the interventional glaucoma paradigm that we’ve talked about in the past. And we would expect more and more practices both through the investment of new surgeons as well as shifting of their own allocation of time for them to be spending more and more time treating glaucoma patients with minimally invasive solutions just like iDose and others. And we put forward and we are putting forward a significant amount of investment to drive that change in the standard of care over the course of many years as we move forward here.

Joanne Wuensch: Thank you.

Operator: Our next question comes from David Saxon at Needham and Company.

David Saxon: Great. Good afternoon. Thanks for taking my questions. Maybe I’ll start on the US Glaucoma sales force. Are you doing anything to compensation or incentives to ensure there’s a focus on the iDose launch, but to also make sure they’re not forgetting, like inject, infinite, etcetera, so the rest of the US business doesn’t, kind of stall out?

Joseph E. Gilliam: Yes, David. Well, the short answer is yes. And clearly, we’ve got a pretty well-structured strategy as it comes to compensation both as it relates to new product launches as well as existing business. We’re deploying that here. It’s absolutely an art, not a science when it comes to doing that, but we think we’ve got the right balance of continuing to drive, really three things. First is, as you referenced, the iDose launch and activities around that. Second, the other areas of the business in terms of revenue generation whether that be iStent inject or certainly iStent infinite as we continue to drive that forward. And third, really incentivizing the kind of behaviour to support what I just answered in the last call, which is putting in place those foundational building blocks and driving the activities that we think will expand the market, over the next several years and certainly the next decade as we think about what’s going to really matter to drive in this business, not just in 2024, but far beyond.

David Saxon: Great. That’s helpful. And then, just on the pipeline, looking at iLution, so phase 2a, started in the fourth quarter, what are the milestones this year, for that pipeline product and what’s a reasonable expectation for when that could be commercial? Thanks so much.

Thomas W. Burns: Yes, David. I’ll be answering the first part of your question. We’re going to be looking at assessing completing and assessing that clinical trial for iLution Travoprost this year, and we expect to be able to have data in hand by the end of this year. And when we see that data, we’ll then make determinations on how we go forward into a potential Phase 3. So I can’t ask the second part of your question, but I can tell you that we’re excited about iLution both with Travoprost and then you’ve seen the data as well of iLution and the use of dry eye where we saw substantial changes in visual acuity as well as substantial improvements in tear film stability. So these are two leading candidates and APIs for this new platform that we hope will be a significant contributor for us in the future.

David Saxon: Great. Thanks so much.

Operator: We’ll move next to Anthony Petrone at Mizuho Group. And, Anthony, your line is open. You may have yourself muted. Hearing no response, we’ll move next to Sam Brodovsky at Truist Securities.

Sam Brodovsky: Hey. Can you hear me okay?

Thomas W. Burns: Yes. We can.

Sam Brodovsky: Great. Thanks for taking the question. I’ll just squeeze two quick ones in on iDose. Just I think you had mentioned second half assumption for the J-Code for the permanent. Can I nail you down on whether the guidance assumes July 1 or October 1? And then on the ASP, any incremental color on what the realized ASP is going to be and how much we can expect in terms of gross to net or a discount there?

Joseph E. Gilliam: Yes, sure, Sam. It’s Joe. I think maybe to put a little bit more color just in terms of the technical dates that were behind what Tom suggested. By putting in that application, prior to the end of the year, you would assume that the CMS cycle would deliver a J-Code starting July 1. That also then translates into, reported ASPs by the fourth quarter, both of which each of those are incremental drivers in terms of creating a seamless, call it market access or reimbursement environment around that that J-Code and overall iDose. As you think about, really the broader dynamic around the iDose launch, those things are going to be real key drivers as we’ve talked about alongside the training initiatives and the things that are there to unlock, if you will, the iDose opportunity as we move forward.

And, and I know you had a second question as well. Gross to net. Yeah. So as we’ve talked about, we will not be doing, rebating associated with the iDose product. But where you will see that is obviously in government related programs where there’s standard discounts. And so over time, a portion of our revenues, we realize that, that 23% discount that’s typical with government related programs. So I think it’s probably fair to say this will that we’ll keep you apprised as we move forward that, realized ASP somewhere in the $13,000 range is probably a safe place to start from a modeling perspective, and we’ll dial that in over time as our mix becomes more clear.

Sam Brodovsky: Great. Thanks for taking the questions.

Operator: And at this time, that does conclude the question-and-answer session. I would like to turn the conference back over to management for closing remarks.

Thomas W. Burns: Okay. I want to thank you all for your time and attention today. And we also thank you for your continued interest and support of Glaukos. Goodbye.

Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect.